Business context and reporting period
Nature’s Sunshine Products, Inc. sells nutritional and personal-care products through independent consultants and direct sales. This Form 10-Q covers the three months ended March 31, 2023, compared with the same period in 2022. Amounts below are in U.S. dollars; financial statement amounts are in millions unless otherwise noted.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Net sales | $108.6 | $110.5 |
| Gross profit / margin | $76.9 / 70.8% | $76.0 / 68.8% |
| Operating income / margin | $0.2 / 0.2% | $1.3 / 1.2% |
| Net income (loss) | $1.3 | $(2.7) |
| Net income (loss) attributable to common shareholders | $0.9; diluted EPS $0.04 | $(3.0); diluted loss per share $0.15 |
| Cash from operating activities | $9.3 | $(7.9) |
| Capital expenditures | $2.3 | $1.5 |
Cash and cash equivalents were $65.7 million at March 31, 2023, versus $60.0 million at year-end 2022. Working capital was $82.8 million, down from $83.9 million. Cash increased $5.7 million during the quarter. Of cash on hand, $61.0 million was held in foreign markets and may face withholding taxes or other repatriation restrictions; $4.7 million was held in the U.S.
Debt included $0.2 million outstanding under the revolving credit agreement and $0.9 million under the equipment-related credit agreement, all classified as current. The company reported compliance with credit covenants. The revolving facility has a $25 million borrowing limit and matures July 1, 2027. Operating lease liabilities are additional obligations. Management believes cash, operating cash generation, and available resources will fund normal operating needs.
Changes versus the prior comparable period
- Reported sales decreased 1.7%, while sales in local currencies increased 2.4%; foreign exchange reduced sales by approximately $4.6 million.
- Gross margin improved by 2.0 percentage points, primarily because Q1 2022 included $3.1 million of inventory valuation reserves related to the Russia-Ukraine conflict. Inflation and unfavorable currency movements partly offset the improvement.
- SG&A rose $3.0 million to $43.6 million, or 40.2% of sales versus 36.8%, primarily reflecting the $5.8 million Japan fraud and investigation charge. Lower China service fees and compensation expense partly offset the increase.
- Operating income declined 86.9%, to $0.2 million. Other income was $1.5 million, primarily from foreign-exchange gains, versus a $0.3 million loss a year earlier. The tax provision fell to $0.4 million from $3.7 million; the prior-year effective tax rate was unusually high at 369.9%, largely due to a valuation allowance against deferred tax assets.
- Operating cash flow improved by $17.2 million, with management citing improved earnings and timing of liability payments and receivables, as well as lower inventory purchases.
Outlook, risks, contingencies, and unusual items
The filing provides no specific revenue or earnings guidance. Management identifies expected improvement in gross profit and gross margin as a forward-looking objective and says it expects available resources to cover normal operating needs. Actual results remain subject to significant uncertainty.
- Japan fraud and control weakness: Fraudulent wire transfers at wholly owned Synergy Japan totaled $4.8 million; the company also recorded $1.0 million of investigation and professional fees. Management reported no evidence of additional fraud or unauthorized access to consumer or other company data. The incident revealed a material weakness in controls over wire transfers, and disclosure controls and internal control over financial reporting were deemed ineffective at March 31, 2023. Remediation was underway but not complete.
- Market and operating risks: The company cited inflation, foreign-exchange volatility, supply-chain and manufacturing disruptions, consultant retention and productivity, regulation of products and direct selling, and continuing effects of COVID-19. It expects the Russia-Ukraine conflict to affect the business for the foreseeable future; Q1 2023 had no related charge, compared with $3.1 million in Q1 2022.
- Contingencies: Accrued non-income tax contingencies were $0.3 million, with potential future payments estimated at $0–$2.9 million. Accruals for other litigation were $0.5 million, with potential payments estimated at $0–$0.4 million; additional matters could result in losses, but were not considered probable or estimable. The company also noted open tax years in U.S. and foreign jurisdictions.
- Capital returns: The company repurchased 90,000 shares for $0.8 million during the quarter; $23.2 million remained available under its repurchase authorization. Future repurchases are discretionary.
Important facts for investors to verify
- Progress and independent validation of remediation for the material weakness, and whether further losses, misstatements, or restatements arise.
- Whether any of the $4.8 million Japan wire-transfer loss is recovered; the filing does not provide a clear recovery amount.
- Whether gross-margin improvement persists after excluding the prior-year Russia-related inventory reserve benefit, and how inflation and currency movements affect margins.
- Cash accessibility, given that most cash is held outside the U.S., and the company’s ability to sustain positive operating cash flow.
- Developments in tax and legal contingencies, consultant activity, and sales trends in key markets, including South Korea, Taiwan, China, and North America.